Managing Agitation Associated with Schizophrenia and Bipolar Disorder in the Emergency Setting

Scott L Zeller, Leslie Citrome, Scott L Zeller, Leslie Citrome

Abstract

Introduction: Patient agitation represents a significant challenge in the emergency department (ED), a setting in which medical staff are working under pressure dealing with a diverse range of medical emergencies. The potential for escalation into aggressive behavior, putting patients, staff, and others at risk, makes it imperative to address agitated behavior rapidly and efficiently. Time constraints and limited access to specialist psychiatric support have in the past led to the strategy of "restrain and sedate," which was believed to represent the optimal approach; however, it is increasingly recognized that more patient-centered approaches result in improved outcomes. The objective of this review is to raise awareness of best practices for the management of agitation in the ED and to consider the role of new pharmacologic interventions in this setting.

Discussion: The Best practices in Evaluation and Treatment of Agitation (BETA) guidelines address the complete management of agitation, including triage, diagnosis, interpersonal calming skills, and medicine choices. Since their publication in 2012, there have been further developments in pharmacologic approaches for dealing with agitation, including both new agents and new modes of delivery, which increase the options available for both patients and physicians. Newer modes of delivery that could be useful in rapidly managing agitation include inhaled, buccal/sublingual and intranasal formulations. To date, the only formulation administered via a non-intramuscular route with a specific indication for agitation associated with bipolar or schizophrenia is inhaled loxapine. Non-invasive formulations, although requiring cooperation from patients, have the potential to improve overall patient experience, thereby improving future cooperation between patients and healthcare providers.

Conclusion: Management of agitation in the ED should encompass a patient-centered approach, incorporating non-pharmacologic approaches if feasible. Where pharmacologic intervention is necessary, a cooperative approach using non-invasive medications should be employed where possible.

References

    1. Holloman GH, Jr, Zeller SL. Overview of project BETA: Best practices in Evaluation and Treatment of Agitation. West J Emerg Med. 2012;13(1):1–2.
    1. Wilson MP, Pepper D, Currier GW, et al. The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project Beta Psychopharmacology Workgroup. West J Emerg Med. 2012;13(1):26–34.
    1. Knox DK, Holloman GH., Jr Use and avoidance of seclusion and restraint: consensus statement of the American Association for Emergency Psychiatry Project BETA Seclusion and Restraint Workgroup. West J Emerg Med. 2012;13(1):35–40.
    1. Weiss AP, Chang G, Rauch SL, et al. Patient- and practice-related determinants of emergency department length of stay for patients with psychiatric illness. Ann Emerg Med. 2012;60(2):162–71.
    1. Marder SR. A review of agitation in mental illness: treatment guidelines and current therapies. J Clin Psychiatry. 2006;67(Suppl 10):13–21.
    1. National Institute for Health and Care Excellence (NICE) Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. 2014. [Accessed Sep 11, 2015]. Available at: .
    1. Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41:263–306.
    1. Richmond JS, Berlin JS, Fishkind AB, et al. Verbal de-escalation of the agitated patient: consensus statement of the American Association for Emergency Psychiatry Project BETA De-escalation Workgroup. West J Emerg Med. 2012;13(1):17–25.
    1. Stowell KR, Florence P, Harman HJ, et al. Psychiatric evaluation of the agitated patient: consensus statement of the American Association for Emergency Psychiatry Project BETA Psychiatric Evaluation Workgroup. West J Emerg Med. 2012;13(1):11–6.
    1. Nordstrom K, Zun LS, Wilson MP, et al. Medical evaluation and triage of the agitated patient: consensus statement of the American Association for Emergency Psychiatry Project BETA Medical Evaluation Workgroup. West J Emerg Med. 2012;13(1):3–10.
    1. Strout TD. Psychometric testing of the Agitation Severity Scale for acute presentation behavioral management patients in the emergency department. Adv Emerg Nurs J. 2014;36(3):250–70.
    1. Swift RH, Harrigan EP, Cappelleri JC, et al. Validation of the Behavioural Activity Rating Scale (BARS): a novel measure of activity in agitated patients. J Psychiatr Res. 2002;36(2):87–95.
    1. Kopecky HJ, Kopecky CR, Yudofsky SC. Reliability and validity of the Overt Agitation Severity Scale in adult psychiatric inpatients. Psychiatr Q. 1998;69(4):301–23.
    1. Silver JM, Yudofsky SC. The Overt Aggression Scale: overview and guiding principles. J Neuropsychiatry Clin Neurosci. 1991;3(2):S22–9.
    1. Montoya A, Valladares A, Lizan L, et al. Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health Qual Life Outcomes. 2011;9:18.
    1. Lindenmayer JP, Brown E, Baker RW, et al. An excitement subscale of the Positive and Negative Syndrome Scale. Schizophr Res. 2004;68(2–3):331–7.
    1. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–76.
    1. Zeller SL, Rhoades RW. Systematic reviews of assessment measures and pharmacologic treatments for agitation. Clin Ther. 2010;32(3):403–25.
    1. Pines JM, Batt RJ, Hilton JA, et al. The financial consequences of lost demand and reducing boarding in hospital emergency departments. Ann Emerg Med. 2011;58(4):331–40.
    1. Cole R. Reducing restraint use in a trauma center emergency room. Nurs Clin North Am. 2014;49:371–81.
    1. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study. JAMA. 1990;264(19):2511–8.
    1. Morrow T. Old drug in new package promises to calm the agitated. Manag Care. 2014;23(4):50–1.
    1. Allen MH, Currier GW, Carpenter D, et al. The expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract. 2005;11(Suppl 1):5–108. quiz 110–2.
    1. Janssen Pharmaceuticals, Inc. Haldol Prescribing Information. 2013. [Accessed Sep 11, 2015]. Available at: .
    1. Jhee SS, Zarotsky V, Mohaupt SM, et al. Delayed onset of oculogyric crisis and torticollis with intramuscular haloperidol. Ann Pharmacother. 2003;37(10):1434–7.
    1. Pfizer Inc. Geodon Prescribing Information. 2014. [Accessed Sep 11, 2015]. Available at: .
    1. Eli Lilly and Company. Zyprexa Prescribing Information. 2014. [Accessed Sep 11, 2015]. Available at: .
    1. Otsuka Pharmaceutical Company. Abilify Prescribing Information. 2012. [Accessed Sep 11, 2015]. Available at: .
    1. Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry. 2007;68(12):1876–85.
    1. Janssen Pharmaceuticals, Inc. Risperdal Prescribing Information. 2014. [Accessed Sep 11, 2015]. Available at: .
    1. Teva Pharmaceuticals USA I. Adasuve Prescribing Information. 2015. [Accessed Sep 11, 2015]. Available at: .
    1. Nordstrom K, Allen MH. Alternative delivery systems for agents to treat acute agitation: progress to date. Drugs. 2013;73(16):1783–92.
    1. Van Schaick EA, Lechat P, Remmerie BM, et al. Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clin Ther. 2003;25:1687–99.
    1. Thyssen A, Remmerie B, D’Hoore P, et al. Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability. Clin Ther. 2007;29(2):290–304.
    1. Actavis Inc. Saphris Prescribing Information. 2015. [Accessed Sep 11, 2015]. Available at: .
    1. Pratts M, Citrome L, Grant W, et al. A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatr Scand. 2014;130(1):61–8.
    1. Zisook S, Click MA., Jr Evaluations of loxapine succinate in the ambulatory treatment of acute schizophrenic episodes. Int Pharmacopsychiatry. 1980;15(6):365–78.
    1. Lesem MD, Tran-Johnson TK, Riesenberg RA, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry. 2011;198(1):51–8.
    1. Kwentus J, Riesenberg RA, Marandi M, et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord. 2012;14(1):31–40.
    1. Citrome L. Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents. Ther Clin Risk Manag. 2013;9:235–45.
    1. Zedie N, Amory DW, Wagner BK, et al. Comparison of intranasal midazolam and sufentanil premedication in pediatric outpatients. Clin Pharmacol Ther. 1996;59(3):341–8.
    1. Powney MJ, Adams CE, Jones H. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) Cochrane Database Syst Rev. 2012;11:CD009377.
    1. Citrome L. Review: Limited evidence on effects of haloperidol alone for rapid tranquillisation in psychosis-induced aggression. Evid Based Ment Health. 2013;16(2):47.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa